Influenza trivalent vaccine (Cadila Healthcare)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfluenza trivalent vaccine (Cadila Healthcare)
Drug Alias Name三价流感疫苗 - Cadila HealthcareTrivalent influenza vaccine流感三价疫苗 - Cadila Healthcare
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCentral Nervous System NeoplasmsMultiple MyelomaNeoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesZydus Lifesciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZydus Lifesciences LtdNational Cancer Institute
Inactive CompaniesWake Forest University Health SciencesWashington University School Of MedicineUniversity of Nebraska
Active IndicationsInfluenza, HumanHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsCentral Nervous System NeoplasmsMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A